08:00 , Jan 27, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Paraoxonase-1 (^PON-1) genotyping to guide use of clopidogrel to prevent stent thrombosis PON-1 genotyping could be used to avoid prescribing...
08:00 , Jan 27, 2011 |  BC Innovations  |  Tools & Techniques

Once a PON-1 an enzyme

In March 2010, the FDA added a boxed warning to the blockbuster drug Plavix clopidogrel, an antiplatelet agent, noting that carriers of variants of the liver enzyme cytochrome P450 2C19-present in up to 14% of...
07:00 , Oct 30, 2008 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Neutral drift libraries...
07:00 , Aug 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Other ...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

BioLineRx, Tel-Aviv Sourasky Medical Center, Weizmann Institute of Science deal

BLRX received exclusive worldwide rights to develop and commercialize two preclinical therapeutic candidates. The institute and center’s BL-3040 is a selective estrogen receptor modulator to treat estrogen-regulated malignancies and osteoporosis. The institute’s BL-3050 is a...